

Beyond the Label: Steering the Focus Toward Safe and Effective Prescribing

Date:

Apr 2017
Visit Article

Each year, hundreds of millions of prescription medications are dispensed to pediatric patients. A significant proportion of prescriptions are used in an off-label manner, outside the specifications approved by the US Food and Drug Administration (FDA), rendering off-label prescribing a "public health issue for infants, children and adolescents," as described by the Committee on Drugs for the American Academy of Pediatrics. The committee also explicitly states that off-label use "does not imply an improper, illegal, contraindicated or investigational use." Yet, when used in research, clinical practice, or even the lay media, the term off-label commonly carries a negative connotation. This interpretation probably reflects the sense of uncertainty in understanding the risk—benefit balance of a medication without FDA review and approval. However, prescribing according to the package insert does not necessarily translate to the safe and effective use of a medication. The clinical trial data required for FDA approval often represent highly select populations in controlled settings with limited follow-up. These data may not translate well to real-world use, hence the need for postmarketing surveillance and research. Conversely, lack of pediatric labeling for a medication does not necessarily indicate a lack of evidence. It may simply mean the pharmaceutical company has not submitted an application for FDA approval to add a new indication or population.

Journal:

Pediatrics

Authors:

Czaja AS, Fiks AG, Wasserman RC, Valuck RJ, Comparative Effectiveness Research Through Collaborative Electronic Reporting (CER 2) Consortium

Related Content

Variations in Mental Health Diagnosis and Prescribing Across Pediatric Primary Care Practices